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Abstract
Introduction: Tamsulosin is an -1A-specific blocker inducing selective relaxation of ureteral smooth
muscle and inhibition of ureteral spasms leading to ureteral dilatation that can facilitates retrograde
ureterorenoscopy (URS).
Objective: To assess the efficacy of tamsulosin in improving the outcome of URS management of lower
ureteral stones.
Patients and methods: This prospective, randomised, controlled, clinical trial was carried out between June
2011 and December 2014. It included 98 patients with lower ureteral stones scheduled for treatment with
URS. Before URS, patients were randomly divided into 2 groups; study group including 51 patients, in which
pre-URS daily oral dose of tamsulosin 0.4 mg tab, for 1 week, was given and control group including 47
patients who received no additional therapy rather than standard analgesic on demand. The URS outcomes
were evaluated and compared between both groups.
Results: The demographic and stone characteristics were comparable between both groups. The mean URS
time was significantly shorter in study group than in control group (52.0 ± 14.9 min vs. 71.0 ± 17.3 min;
, 89 (90.81%) had a successful URS procedures. The success rate wasp = 0.039). Of the 98 patientsPlease cite this article in press as: Abdelaziz AS, Kidder AM. Tamsulosin therapy improved the outcome of ureterorenoscopy for lower
ureteral stones: A prospective, randomised, controlled, clinical trial. Afr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2015.12.003
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94.1% (98/51) in study group compared 89.2% (58/65) in the control group, with statistically significant
difference (p = 0.045). The major complications occurred in 4.25% of patients in control group but in only
1.96% of those received tamsulosin (p = 0.034).
Conclusion: Post-tamsulosin ureteroscopy was easier and safer; leading to significantly increased stone-free
rates and fewer complications.
© 2016 Pan African Urological Surgeons Association. Production and hosting by Elsevier B.V. This is an open
the CC
I
U
p
a
(
f
u
p
S
i
w
h
i
a
U
t
a
U
T
c
e
c
r
d
e
r

m
a
o
e
r
p
o
u
P
A
p
f
e
c
A
s
P
t
a
b
a
(
a
p
o
(
h

P
I
(
g
t
O
U
r
(
p
s
n
s
d
u
l
a
s
c
f
u
T
a
F
A
s
U
>
t
r
URS complications were reported according to the modified Clavien
grading system. Grade I (events without adverse consequences foraccess article under
ntroduction
reterorenoscopy (URS) is one of the most common procedures
erformed for upper and lower ureteral disorders. However, URS is
ssociated with potential risks and complications [1]. A percentage
5–10%) of patients undergoing URS requires a second procedure
or definitive management as the result of failure to access the
reter. The treatment of patients who have undergone a failed URS
rocedure or who experience complications may be complex [2,3].
ubstantial advances in URS have resulted in the procedure being
ncorporated into routine urological practice in many centres world-
ide. An abundance of clinical data and technological progression
as enabled the development of novel solutions, which have
ncreased the efficacy of URS and reduced associated morbidity
nd costs [4].
reteroscopic complications are well known, but the predictive fac-
ors remain unclear. Careful attention to the selection of instruments
nd techniques is important to reducing complications related to
RS procedures [1].
o facilitate ureteral stone expulsion and decrease post-operative
omplications, recent studies have recommended a medical
xpelling therapy (MET) with calcium antagonists, nifedipine, corti-
osteroids and -1 blockers [5–7]. Different subtypes of adrenergic
eceptors, such as 1a, 1b and 1d, have been identified in the
istal ureter, with a higher density of 1d compared to the oth-
rs. Several studies have demonstrated increased stone expulsion
ates for distal ureteral calculi using tamsulosin as a highly selective
1d adrenoceptor antagonist, which inhibits contraction of ureteral
usculature, reduces basal tone, decreases peristaltic frequency and
mplitude and decreases intraluminal pressure [5–8]. Based on these
bservations, we hypothesised that MET with -1d blocker before
ndoscopic treatment of ureteral stones may increase the success
ate of the procedure and decrease operative complications. The
resent study aimed to evaluate the efficacy of tamsulosin therapy
n the feasibility and success rate of URS management for lower
reteral stones.
atients and methods
fter receiving local institutional review board approval, this
rospective, randomised, controlled clinical trial was performed
rom June 2011 to December 2014. The study protocol was
xplained to all participants, and they provided written informed
onsent prior to inclusion.Please cite this article in press as: Abdelaziz AS, Kidder AM. Tamsulo
ureteral stones: A prospective, randomised, controlled, clinical trial. A
ll patients ≥18 years old with a single, radio opaque, lower ureteral
tone, 5–10 mm in maximum diameter were included in the study.
atients were evaluated via medical histories, physical examina-
ions and laboratory investigations in the form of complete urine
t
o
v
iBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
nalysis, urine culture, blood urea and serum creatinine, complete
lood cell count, liver function tests and coagulation profile. In
ddition, abdominal X-rays for kidneys, ureters and urinary bladder
KUB), urinary ultrasonography and intravenous urography (IVU)
nd/or abdominal computed tomography (CT) were performed in all
atients. Pregnant women and patients with a history of endoscopic
r open ureteral surgery, persistent renal pain, urinary tract infection
UTI), renal impairment, solitary kidney, bilateral ureteral stones,
igh-grade hydronephrosis and those on or with hypersensitivity to
-blockers were excluded from the study.
atients were randomised into two equal groups using a coin toss.
n the study group, patients received a daily oral dose of tamsulosin
0.4 mg) for one week before URS, whereas no active treatment was
iven to members of the control group. All patients were asked to
ake analgesics (NSAIDs) for moderate and severe pain.
perative technique
nder spinal or general anaesthesia, cystoscopy was initially car-
ied out to identify the ureteral orifice. A floppy-tipped guidewire
0.038 in.) was inserted into the ureter. After the guidewire was
laced, URS was performed using a 7.5 F semi-rigid ureteroreno-
cope (Karl Storz, Tuttlingen, Germany). Ureteral dilatation was
ot routinely performed during ureteroscopy except when the truly
tenotic ureteric orifice was encountered. Ureteral dilatation was
one by balloon dilation systems, which were introduced into the
reter over a guidewire. Disintegration using the Swiss pneumatic
ithoclast was performed, and the stone gravel was retrieved using
Dormia basket and/or grasper forceps to ensure removal of all
izable gravel. A ureteric stent was inserted at the end of the pro-
edure for a period of 1–2 days. Internal stents (JJ) were placed
or 4–6 weeks in cases with intra-operative complications (e.g.
reteral perforation, false passage) and in solitary kidney patients.
he procedure site was covered with perioperative antibiotics and
nalgesics.
ollow-up and outcome measurements
ll patients were evaluated with X-ray KUB and urinary ultra-
onography 24 h and 2 weeks after URS. The primary endpoint was
RS success, which was defined as no evidence of residual stones
2 mm in diameter and no or minimal complications. The opera-
ive time, fluoroscopy time, peri-operative complications, stone-free
ate, use of ureteral stents and hospital stay were recorded. Thesin therapy improved the outcome of ureterorenoscopy for lower
fr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2015.12.003
he patient), grade II (complications comprising blood transfusions
r urinary tract infection), grade IIIa (complications requiring inter-
ention under local anaesthesia), grade IIIb (complications requiring
ntervention under general anaesthesia), grade IVb (single organ
ARTICLE IN PRESSAFJU-312; No. of Pages 6
Tamsulosin therapy improved the outcome of ureterorenoscopy for lower ureteral stones 3
               paents with 
lower ureteric ston e 
n=176
           Randomised  paents who 
met the inclus ion criteria 
n= 121
Study group (paent 
 take tamsolusin 
0.4mg/ day n= 60
Complete d n=51
Control group 
paent take 
plac ebo /day       
n= 61
Complete d n=47
Excluded paents :( n= 9)
Pass ing ston es (n=1)
Noncomplia nce (n=2) 
Develo pment of UTI (n=2)
Lost to follow up (n=2)
Consent wit hdrawn (n=2)
Exc luded paents :( n= 14 )
Pass ing ston es (n=1)
Noncom plia nce (n=4) 
Develo pment of UTI (n=3)
Lost to follow up (n=3)
Consent wit hdrawn (n=3)
Excl uded (n= 55):
Not mee ng i ncl usio n criteria 
(n= 38)
Ref used to parcipate (n= 17)
Screened
domi
O
i
s
s
p
(
(
t
i
c
f
s
r
T
p
I
s
a
p
p
g
s
DFigure 1 Patient ran
dysfunction, such as myocardial infarction and renal failure), grade
IVb (urosepsis or multi organ dysfunction) and grade V (death) [9].
Statistical analysis
Data analysis was performed using the software programme SPSS
17.0 for Windows XP. The t-test and Mann–Whitney test were used
for comparison of the numerical variables. The categorical vari-
ables were compared using the chi-square and Fisher exact test.
Significance was considered as a p-value <0.05.
Results
A total of 121 patients met the inclusion criteria; 23 patients
were excluded due to noncompliance issues, development of pre-
intervention UTIs, passing stones or lost follow-up. Hence, 98
patients were ultimately included: 51 patients in the study group
and 47 patients in the control group (Fig. 1). There were no statis-
tically significant differences between patients in the two groups in
regard to their demographic and stone characteristics (Table 1).
Operative time was significantly shorter in the study group
(52.0 ± 14.9 min vs. 71.0 ± 17.3 min; p = 0.039), and most patientsPlease cite this article in press as: Abdelaziz AS, Kidder AM. Tamsulo
ureteral stones: A prospective, randomised, controlled, clinical trial. A
in this group did not require ureteral dilatation during URS (82.35%
vs. 42.55%; p = 0.024). The mean hospitalisation time, operative
time and the need for ureteral dilatation and stenting in both groups
are demonstrated in Table 2.
R
t
osation and disposition.
ut of 98 patients, 89 (90.81%) were successfully managed by URS
n the first session while five (5.10%) were cured in the second
ession. The overall success rate was significantly higher in the
tudy group compared to the control group (94.11% vs. 87.23%;
= 0.045). Failure of the first URS procedure occurred in nine
9.18%) cases: due to the failure to pass the guidewire in three
3.06%), failure of ureteral dilatation in three (3.06), stone migra-
ion in two (2.04%) and ureteral perforation prior to stone extraction
n one case (1.02%). During the second URS session, one out of six
ases had a URS failure due to perforation of the ureter. The overall
ailure rate was significantly higher in the control group than in the
tudy group (six vs. three; p = 0.041). The URS success and failure
ates are shown in Table 3.
he overall complication rate was 14.28%, affecting six (11.76%)
atients in the study group and nine (19.14%) in the control group.
n the study group, three patients showed grade I complications, one
howed grade II complications, one showed grade IIIa complications
nd one showed grade IIIb complications. In the control group, five
atients showed grade I complications, one showed grade II com-
lications, one showed grade IIIa complications and two showed
rade IIIb complications (Table 4). All reported complications were
uccessfully managed either conservatively or endoscopically.
iscussionsin therapy improved the outcome of ureterorenoscopy for lower
fr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2015.12.003
ecent advances in endourology techniques and new instrumenta-
ion have largely shifted the treatment of ureteral stones away from
pen surgery to either minimally invasive methods (e.g. ESWL and
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Table 1 Characteristics data in patients submitted to ureteroscopy in both groups.
Characteristics Patients Treatment groups (n = 98) p Value
Study group Control group
Patient, n 98 51 47 0.791
Age, mean ± SD, y 36.27 ± 6.7 35 38 0.818
Sex, n (%) Male 64 34 30 0.812
Female 34 17 17 0.505
Side Right 45 23 22 0.592
Left 53 28 25 0.611
Stone size mean ± SD/mm 6.4 ± 2.7 (4–9) 6.6 ± 2.3 (5–9) 6.2 ± 3.2 (4–9) 0.631
Table 2 Intra-operative characteristics of patients.
Study group (n = 51) Control group (n = 47) Overall (n = 98) p Value
Operative time (min) 52.0 ± 14.9 71.0 ± 17.3 60.2 ± 15.1 0.039*
Fluoroscopy time (s) 71.7 ± 62.6 86.0 ± 80.1 79.2 ± 76.0 0.049*
Ureteral dilatation % (n) 17.64 (9) 48.29 (27) 36.73 (36) 0.041*
Complications % (n) Major 1.96 (1) 4.25 (2) 3.06 (3) 0.040*
Minor 7.84 (4) 11.7 (5) 10.01 (9) 0.076
Stone free % (n) 94.11 (48) 87.23 (41) 90.81 (89) 0.045*
Ureteral stent % (n) Catheter 58.82 (30) 72.34 (34) 65.30 (64) 0.047*
JJ 11.76 (6) 19.14 (9) 15.3 (15) 0.045*
No stent 29.41 (15) 8.51 (4) 19.38 (19) 0.029*
Length of stay (days) 1.2 ± 0.6 1.7 ± 0.9 1.3 ± 0.8 0.072
Retreatment or
secondary
intervention
URS 3 (5.88%) 6 (12.76%) 9 (9.18%) 0.041*
SWL 1 (1.96%) 1(2.12%) 2 (2.04%) 0.041*
Ureterolithotomy 0 2 (4.25%) 2 (2.04%) 0.011*
* p < 0.05; p value by Student’s-t-test and chi-square test.
Table 3 Characteristics of success (free stone) and retreatment of patients with failed initial procedure.
Retreatment patients Initial ureteroscopy Re-ureteroscopy Others modalities
ESWL Ureterolithotomy
Study
group
(n = 51)
Control
group
(n = 47)
Study
group
(n = 2)
Control
group
(n = 4)
Study
group
(n = 1)
Control
group
(n = 1)
Study
group
(n = 0)
Control
group
(n = 2)
Identification of
ureteric orifice
Success 50 45 2 4 0 0 0 0
Failed 1 2 0 0 0 0 0 0
Dilatation of ureter Not need 16 4 0 0 0 0 0 0
Success 33 39 2 4 0 0 0 0
Failed 1 2 0 0 0 0 0 1
Stone migrations No 48 41 2 4 0 0 0 0
Yes 1 1 0 0 1 1 0 0
Perforation of ureter No 49 41 2 3 0 0 0 0
Yes 1 2 0 1 0 0 0 1
U
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rTotal stone free Success 48 41 2
Failed 3 6 0
RS) or even watchful waiting. Moreover, accurate prediction of
tone passage may prevent unnecessary intervention and possible
omplications, especially for distal ureteric stones. The choice of
he ideal type of therapy is largely related to the type of equipment
vailable, the type, size, position, degree of impaction and obstruc-
ion of the stone, patient preference and the skills and experiences
f the surgeon [10,11]. Current guidelines recommend ureteroscopyPlease cite this article in press as: Abdelaziz AS, Kidder AM. Tamsulo
ureteral stones: A prospective, randomised, controlled, clinical trial. A
ver other treatments including SWL for the majority of ureteric
tones [6].
u
U3 1 1 0 2
1 0 0 0 0
lthough ureteral stones less than 5 mm could pass in up to 98% of
ases, fragmented stones following lithotripsy interventions cause
ome degree of ureteral wall congestion and oedema, interfering
ith straight gravel passing and even leading to stone impaction
nd obstruction. Thus, the use of MET necessitates stone passage
nd decreases the time for spontaneous gravel passage as well as
educing possible risks of renal damage due to prolonged partialsin therapy improved the outcome of ureterorenoscopy for lower
fr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2015.12.003
reteral obstruction (greater than 4–6 weeks) and persistent pain or
TI [12,13].
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Table 4 The complications and their grades according to the MCCS.a
Grade Complications Study group
(n = 51)
Control group
(n = 47)
Overall
(n = 98)
p Value
Minor Grade I Mucosal injuries 1 1 2 0.505
Hematuria 1 2 3 0.034a
Urine retentions 0 1 1 0.024a
Mechanical failure 1 1 2 0.505
Grade II Urinary tract infections 1 1 2 0.024a
Major Grade IIIa Proximal stone migrations 1 1 2 0.505
Grade IIIb Ureteral perforation 1 2 3 0.034a
Grade IVa Myocardial infarction,
pulmonary embolism
0 0 0 0.0
Grade IVb Urosepsis 0 0 0 0.0
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TGrade V Death
a MCCS: modified Clavien classification system.
Many recent studies have demonstrated excellent results of MET use
for distal ureteral stones. In terms of stone expulsion and control of
ureteric colic pain, drugs (e.g. calcium channel blockers, nifedipine,
corticosteroids, 1 blockers) that can modulate the function of the
ureter, which may be obstructed by a stone, can be used. Alpha-1
blockers, in particular 1A blockers (e.g. tamsulosin), are preferred
due to the prevalence of a specific adrenoceptor subtype in the dis-
tal part of the ureter. Tamsulosin acts by relaxing the ureteral wall
muscle, facilitating gravel expulsion after lithotripsy and aiding the
forwarding of instruments through the ureter for improved stone
access [10].
Since stone size is the most important factor in all intervention pro-
cedures, URS has higher efficacy and success rates than ESWL, but
it is more expensive and more invasive [11]. If adjunct therapy such
as MET is used before or when the ureteroscope is advanced prior
to accessing the stone, these complications can be reduced.
Many recent studies have demonstrated that the efficacy of -
blockers is preferred to the other MET’s efficacies after ESWL
procedures for proximal ureter stones and the passing of lower
ureter stones. Moreover, -blockers, especially tamsulosin, which
is a highly selective sympatholytic agent, may reduce complications
after stone breaking and gravel passing in all lithotripsy procedures
[14–16].
The exact mechanism of action of -blockers on the ureteral smooth
muscle involves an increase in the expulsion rate of stones or a
decrease in the time it takes for stone expulsion, which suggests
that -adrenergic receptor antagonists should be the preferred MET
for distal stone expulsion [16].
The research group prospectively analysed different factors that
might affect the success and complications of managing ureteric
stones with URS. They found that endoscopic interventions without
preparation with tamsulosin were associated with increased compli-
cation or failure rates. The overall complication rate after URS was
13.07%. Major complications in the form of ureteric perforations
were recorded in three cases (3%): one in group A and two in group
B, and all patients were stented.Please cite this article in press as: Abdelaziz AS, Kidder AM. Tamsulo
ureteral stones: A prospective, randomised, controlled, clinical trial. A
Regarding the modified Clavien classification system, major com-
plications did not occur in our study. However, minor and moderate
complications (Grades I, II and III) were reported in 13.07% of all
patients, consisting of mucosal injuries, haematuria, UTIs or ureteral
o
o
t
o0 0 0 0.0
erforation, which significantly decreased in the study group pre-
ared with tamsulosin. Two cases of ureteral perforation occurred
ith impacted distal ureteric stones (one from each group), and they
ere successfully managed by ureteroscopy after six weeks. Only
ne shifted to open after a failed second ureteroscopy.
tone migration was seen in two patients (2.04%). Due to equip-
ent failure (shortage of equipment for follow-up of the migrating
tones, such as flexible ureteroscopy and laser lithotripsy for frag-
enting or extracting the migrating stones), one patient from each
roup underwent successful re-ureteroscopy and stone removal. In
ddition, ureteroscopy was abandoned in two cases in the control
roup (4.25%) due to insufficient ureteric orifice dilatation.
here was a significantly higher failure rate in the endoscopic pro-
edures in the control group (12.76%) compared to the study group
5.8%). The overall success rate in the present study was 90.8%
94.1% and 87.2% in the study and control groups, respectively).
n 87% stone-free rate has been reported following a single uretero-
copic intervention [17,18].
he researcher noted that the ureteroscopy in patients on tamsu-
osin was more accessible as the ureteral orifice was more open,
ilated, easily visualised and easily intubated without the assis-
ance of a guide wire. Thus, the intramural ureter can be approached
mploying a ‘no-touch’ technique without ureteral dilatation, which
liminates the potential trauma, mucosal irritation, and inadver-
ent manipulation of stones or tumours caused by guidewires and
s particularly helpful when the collection system is evaluated for
ucosal/intra-luminal lesions.
n patients on tamsulosin, the ureteric orifices were easily identified
nd dilated and the ureteroscope could be inserted easily, wirelessly
r over a guidewire, without dilatation, primarily due to the muscle-
elaxing effect of tamsulosin. The present study showed that the
ecessary degree of ureteric orifice dilatation varied significantly
etween the two groups. The ureteric orifice was dilated up to 12 F
n 9 patients (17.64%) in the study group and in 27 patients (48.29%)
n the control group.
he important findings of this research were recorded. First, shortsin therapy improved the outcome of ureterorenoscopy for lower
fr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2015.12.003
perative time was observed when patients were prepared pre-
peratively with tamsulosin. This observation may help to explain
he difficulties sometimes faced in regard to entering the ureter and
vercoming kinking in the ureter resulting from chronic obstruction
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rom ureteric stones, which has an effect on endoscopic stone man-
gement. Therefore, pre-endoscopic preparations might be advised,
articularly in non-urgent cases.
econd, there may be benefits when operating on older male
atients, including decreased operative time and straightening and
ligning of the prostatic urethra.
hird, there were fewer complications and the success rates were
igher when patients were prepared for short periods with tamsu-
osin, which acts as a therapeutic medication in addition to its role
n URS preparation.
his was a blinded study. The surgeon was not aware of the use of
reparation medications to avoid the effect of this knowledge on the
esults of the surgical procedures. However, our study has some lim-
tations. First, relatively few patients were included in each group.
econd, the exact timing of the endoscopic steps, such as bladder
ccess, ureteral access, lithotripsy and ureteral stenting, as well as
ubjective experiences and stone factors such as stone composi-
ion, were not evaluated in the present study. Thus, the results of
his study should be considered as preliminary data, which requires
onfirmation with a larger sample size in the future.
onclusions
ost-tamsulosin ureteroscopy was easier and safer; leading to sig-
ificantly increased stone-free rates and fewer complications.
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